Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 230

Results For "WHO"

2398 News Found

KK Pant is the new NPPA chairman
News | August 12, 2021

KK Pant is the new NPPA chairman

It plays a pivotal role in monitoring pharmaceutical pricing


Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness
Drug Approval | August 12, 2021

Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness

A treatment to prevent extreme symptoms and cut hospitalisation


Global cell expansion market poised for huge growth
Biotech | August 12, 2021

Global cell expansion market poised for huge growth

Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030


Pear Therapeutics’ three FDA authorised prescriptions available at OptumRx
Digitisation | August 11, 2021

Pear Therapeutics’ three FDA authorised prescriptions available at OptumRx

OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.


Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
Biotech | August 11, 2021

Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China

The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial


GSK files application for MMR vaccine in the US
News | August 11, 2021

GSK files application for MMR vaccine in the US

If approved it will bring a second source of MMR vaccine to the US market


GW Pharmaceuticals receives approval for Epidyolex to treat seizures
Drug Approval | August 11, 2021

GW Pharmaceuticals receives approval for Epidyolex to treat seizures

TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines


Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Biotech | August 10, 2021

Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics

Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments


QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements
Drug Approval | August 10, 2021

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab


Kite and Appia Bio collaborate to research and develop Allogeneic cell therapies for cancer
Biotech | August 10, 2021

Kite and Appia Bio collaborate to research and develop Allogeneic cell therapies for cancer

It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies